Years of losses, thin profit margins leave 160 Health feeling down
After two earlier failures, the online healthcare platform’s IPO has been approved by the Hong Kong Stock Exchange Key Takeaways: 160 Health has been approved to list in Hong Kong,…
Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
Akeso shares take a hit despite surging sales of cancer drugs
The maker of oncology drugs posted higher half-year revenues but a widening net loss and share sales by its founders have dented investor confidence Key Takeaways: Drug sales rose 49%…
Anew Health taps investor ‘Qi’ with Nasdaq listing plan
The Hong Kong-based provider of pain relief services using traditional Chinese principles aims to raise about $7.2 million through its U.S. listing, valuing it at up to $200 million Key…
Precision cancer drugs show promise for Kelun-Biotech
The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
Baiyunshan serves up high dividend in lieu of vanilla results
Profits from the company’s Great Health segment rose 14% in the first half of 2025, primarily driven by strong results for its popular Wanglaoji herbal tea Key Takeaways: Baiyunshan’s revenue…
Investors pile into CANbridge stock but can the rally last?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies…
